Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rybak

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
Antibiotics (Basel, Switzerland)|March 31, 2016
Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal TherapySarah J Tennant, Donna R Burgess, Jeffrey M Rybak, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Protein Engineering|April 1, 1997
Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapyD L Newton, Y Xue, L Boqué, et al.
Blood|January 12, 2001
Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphomaD L Newton, H J Hansen, S M Mikulski, et al.
Cell Biophysics|August 1, 1992
Rational immunotherapy with ribonuclease chimeras. An approach toward humanizing immunotoxinsS M Rybak, H R Hoogenboom, D L Newton, et al.
Protein Engineering|November 6, 2003
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragmentJürgen Krauss, Michaela A E Arndt, Andrew C R Martin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
The Journal of Biological Chemistry|November 4, 1992
Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamilyS K Saxena, S M Rybak, R T Davey, et al.
International Journal of Cancer|October 21, 2003
Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphomaMichaela A E Arndt, Jürgen Krauss, Robert Schwarzenbacher, et al.
Leukemia & Lymphoma|August 1, 2002
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeuticsMiriam Hursey, Dianne L Newton, Hans J Hansen, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
Antibiotics (Basel, Switzerland)|March 31, 2016
Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal TherapySarah J Tennant, Donna R Burgess, Jeffrey M Rybak, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Protein Engineering|April 1, 1997
Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapyD L Newton, Y Xue, L Boqué, et al.
Blood|January 12, 2001
Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphomaD L Newton, H J Hansen, S M Mikulski, et al.
Cell Biophysics|August 1, 1992
Rational immunotherapy with ribonuclease chimeras. An approach toward humanizing immunotoxinsS M Rybak, H R Hoogenboom, D L Newton, et al.
Protein Engineering|November 6, 2003
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragmentJürgen Krauss, Michaela A E Arndt, Andrew C R Martin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
The Journal of Biological Chemistry|November 4, 1992
Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamilyS K Saxena, S M Rybak, R T Davey, et al.
International Journal of Cancer|October 21, 2003
Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphomaMichaela A E Arndt, Jürgen Krauss, Robert Schwarzenbacher, et al.
Leukemia & Lymphoma|August 1, 2002
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeuticsMiriam Hursey, Dianne L Newton, Hans J Hansen, et al.
Pageof 19